FIGURE 4.

Psoriasis transcriptome neutralization in PASI50 responders at week 12 of guselkumab (100 or 300 mg; n = 10) versus ustekinumab (90 mg; n = 12) treatment.

(A) Psoriasis transcriptome % neutralization from baseline at week 12. Significant neutralization was defined as false discovery rate < 0.05 and fold change ≥ 2; ≥ 75% recovery defined as significant neutralization and ≥ 75% modulation toward baseline nonlesional levels. (B) Venn diagram illustrating “molecular scar” overlap at week 12. (C) % improvement (lesional versus nonlesional at baseline) of top enriched psoriasis transcriptome genes from baseline at weeks 1 and 12 (red asterisks represent significant difference between treatments via t test, with *p < 0.1, **p < 0.05, ***p < 0.001). DEG, differentially expressed gene; GUS, guselkumab; KC, keratinocyte; LS, lesional; MAD, meta-analysis derived; MADAD, meta-analysis–derived atopic dermatitis; NL, nonlesional; NR, nonresponder; Ph1, phase 1; PSTR, psoriasis transcriptome; RHE, reconstructed human epidermal; UST, ustekinumab.